| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-04 | Erytech Pharma (France) | resignation |
Cancer - Oncology | Resignation | ||
| 2016-01-04 | Vertex Pharmaceuticals (USA-MA) Genomics (UK) | database and state-of-the-art analysis tools |
services contract |
Technology - Services | Services contract | |
| 2016-01-04 | Inovio Pharmaceuticals (USA - PA) | nomination |
Infectious diseases | Nomination | ||
| 2016-01-04 | Global Blood Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2016-01-04 | Erytech Pharma (France) | resignation |
Cancer - Oncology - Rare diseases | Resignation | ||
| 2016-01-04 | Evgen Pharma (UK) | nomination |
Cancer - Oncology - Neurological diseases | Nomination | ||
| 2016-01-04 | Fibrocell Science (USA - PA) Intrexon (USA - MD) | genetically-modified fibroblasts | development |
Inflammatory diseases - Rheumatic diseases | Development agreement | |
| 2015-12-31 | Vivus (USA - CA) Auxilium Pharmaceuticals (USA - MA) Endo International (Ireland) | Stendra®/Spedra® (avanafil) | erectile dysfunction | distribution |
Men's health | Establishment of a new subsidiary in the EU |
| 2015-12-28 | Takeda Pharmaceutical (Japan) Teva Pharmaceutical Industries (Israel) | joint-venture |
Joint-venture agreement | |||
| 2015-12-28 | Immune Pharmaceuticals (USA - MA, Israel) Atlante Biotech (France) | bispecific antibodies | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-12-24 | Galena Biopharma (USA - OR) | resignation |
Cancer - Oncology | Resignation | ||
| 2015-12-22 | Boehringer Ingelheim (Germany) | biopharmaceutical production facility in Vienna (Austria) | construction of new premises | Technology - Services | Construction of new premises | |
| 2015-12-21 | Pharming (The Netherlands) - Hyupjin Corporation (South Korea) | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute angioedema attacks in patients with Hereditary Angioedema (HAE) | commercialisation |
Rare diseases - Genetic diseases | Milestone |
| 2015-12-21 | Novartis (Switzerland) GSK (UK) | ofatumumab | relapsing remitting multiple sclerosis (RRMS) and other autoimmune diseases | product acquisition |
Autoimmune diseases | Product acquisition |
| 2015-12-21 | Array BioPharma (USA - CO) Pierre Fabre (France) | binimetinib (MEK162), encorafenib (LGX818) | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2015-12-21 | Theravectys (France) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2015-12-21 | Kite Pharma (USA - CA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-12-21 | Swedish Orphan Biovitrum - SOBI (Sweden) | nomination |
Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2015-12-21 | NovImmune (Switzerland) | nomination |
Rare diseases - Immunological diseases - Cancer - Oncology | Nomination | ||
| 2015-12-21 | SELLAS Life Sciences (Switzerland) | nomination |
Cancer - Oncology - CNS diseases | Nomination |
